CA1084052A - Process for preparing 4-substituted imidazole compounds - Google Patents
Process for preparing 4-substituted imidazole compoundsInfo
- Publication number
- CA1084052A CA1084052A CA276,559A CA276559A CA1084052A CA 1084052 A CA1084052 A CA 1084052A CA 276559 A CA276559 A CA 276559A CA 1084052 A CA1084052 A CA 1084052A
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- process according
- mole
- aminoethyl
- thiomethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 6
- -1 4-substituted imidazole compounds Chemical class 0.000 title claims description 14
- 238000000034 method Methods 0.000 claims abstract description 43
- 150000001875 compounds Chemical class 0.000 claims abstract description 21
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 51
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 42
- 238000006243 chemical reaction Methods 0.000 claims description 23
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 22
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 12
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 9
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 239000012312 sodium hydride Substances 0.000 claims description 7
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 7
- JEOZNMMOIBLWLV-UHFFFAOYSA-N 2-[(5-methyl-1h-imidazol-4-yl)methylsulfanyl]ethanamine Chemical compound CC=1N=CNC=1CSCCN JEOZNMMOIBLWLV-UHFFFAOYSA-N 0.000 claims description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- HUUUGRYMMWMSCU-UHFFFAOYSA-N 2-[(5-methyl-2-methylsulfanyl-1h-imidazol-4-yl)methylsulfanyl]ethanamine Chemical compound CSC1=NC(CSCCN)=C(C)N1 HUUUGRYMMWMSCU-UHFFFAOYSA-N 0.000 claims description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
- 125000004803 chlorobenzyl group Chemical group 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 150000002460 imidazoles Chemical class 0.000 abstract description 9
- 150000004714 phosphonium salts Chemical class 0.000 abstract description 8
- 239000000543 intermediate Substances 0.000 abstract description 5
- 239000003485 histamine H2 receptor antagonist Substances 0.000 abstract description 4
- 238000006073 displacement reaction Methods 0.000 abstract description 3
- 125000005496 phosphonium group Chemical group 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 description 30
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 28
- 239000000243 solution Substances 0.000 description 26
- CMSYDJVRTHCWFP-UHFFFAOYSA-N triphenylphosphane;hydrobromide Chemical compound Br.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 CMSYDJVRTHCWFP-UHFFFAOYSA-N 0.000 description 25
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 18
- 239000000706 filtrate Substances 0.000 description 16
- 238000001914 filtration Methods 0.000 description 16
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 15
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 15
- 229960003151 mercaptamine Drugs 0.000 description 15
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 12
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- NYYSPVRERVXMLJ-UHFFFAOYSA-N 4,4-difluorocyclohexan-1-one Chemical compound FC1(F)CCC(=O)CC1 NYYSPVRERVXMLJ-UHFFFAOYSA-N 0.000 description 11
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 11
- AVCVDUDESCZFHJ-UHFFFAOYSA-N triphenylphosphane;hydrochloride Chemical compound [Cl-].C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 AVCVDUDESCZFHJ-UHFFFAOYSA-N 0.000 description 10
- 238000010992 reflux Methods 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 150000002431 hydrogen Chemical class 0.000 description 8
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 6
- 239000002585 base Substances 0.000 description 6
- FJKHRICFMSYVFL-UHFFFAOYSA-N 2,2,2-trichloroethanimidamide Chemical compound NC(=N)C(Cl)(Cl)Cl FJKHRICFMSYVFL-UHFFFAOYSA-N 0.000 description 5
- CNMUGSJVSYLQOX-UHFFFAOYSA-N 2-(1h-imidazol-5-ylmethylsulfanyl)ethanamine Chemical compound NCCSCC1=CNC=N1 CNMUGSJVSYLQOX-UHFFFAOYSA-N 0.000 description 5
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- LGDSHSYDSCRFAB-UHFFFAOYSA-N Methyl isothiocyanate Chemical compound CN=C=S LGDSHSYDSCRFAB-UHFFFAOYSA-N 0.000 description 4
- 239000002026 chloroform extract Substances 0.000 description 4
- AQIXAKUUQRKLND-UHFFFAOYSA-N cimetidine Chemical compound N#C/N=C(/NC)NCCSCC=1N=CNC=1C AQIXAKUUQRKLND-UHFFFAOYSA-N 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 150000004820 halides Chemical class 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- ZOHLKTFCEUOOOQ-UHFFFAOYSA-N 4-(methoxymethyl)-5-methyl-1h-imidazole Chemical compound COCC=1N=CNC=1C ZOHLKTFCEUOOOQ-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 239000007868 Raney catalyst Substances 0.000 description 3
- 229910000564 Raney nickel Inorganic materials 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 150000001450 anions Chemical class 0.000 description 3
- OAIVIYSBZFEOIU-UHFFFAOYSA-N chloroform;propan-2-one Chemical compound CC(C)=O.ClC(Cl)Cl OAIVIYSBZFEOIU-UHFFFAOYSA-N 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 125000004149 thio group Chemical class *S* 0.000 description 3
- VFWUYASTZCOUKN-UHFFFAOYSA-N 2-[(5-methyl-1h-imidazol-4-yl)methylsulfanyl]ethanamine;dihydrochloride Chemical compound Cl.Cl.CC=1N=CNC=1CSCCN VFWUYASTZCOUKN-UHFFFAOYSA-N 0.000 description 2
- CWVGPJIFXTUYQA-UHFFFAOYSA-N 2-[(5-methyl-2-methylsulfanyl-1h-imidazol-4-yl)methylsulfanyl]ethanamine;dihydrochloride Chemical compound Cl.Cl.CSC1=NC(CSCCN)=C(C)N1 CWVGPJIFXTUYQA-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- AGOVWWLNTGWMIY-UHFFFAOYSA-N 4-(methoxymethyl)-5-methyl-2-methylsulfanyl-1h-imidazole Chemical compound COCC=1N=C(SC)NC=1C AGOVWWLNTGWMIY-UHFFFAOYSA-N 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- HTPABEPAZTWGPP-UHFFFAOYSA-N 4-chlorobut-3-en-2-one Chemical compound CC(=O)C=CCl HTPABEPAZTWGPP-UHFFFAOYSA-N 0.000 description 2
- 229910000838 Al alloy Inorganic materials 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- IULFXBLVJIPESI-UHFFFAOYSA-N bis(methylsulfanyl)methylidenecyanamide Chemical compound CSC(SC)=NC#N IULFXBLVJIPESI-UHFFFAOYSA-N 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- JQVDAXLFBXTEQA-UHFFFAOYSA-N dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- WCQOBLXWLRDEQA-UHFFFAOYSA-N ethanimidamide;hydrochloride Chemical compound Cl.CC(N)=N WCQOBLXWLRDEQA-UHFFFAOYSA-N 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- WSUNDBVVUCLXTG-UHFFFAOYSA-N methyl n-cyano-n'-[2-[(5-methyl-1h-imidazol-4-yl)methylsulfanyl]ethyl]carbamimidothioate Chemical compound N#CNC(SC)=NCCSCC=1NC=NC=1C WSUNDBVVUCLXTG-UHFFFAOYSA-N 0.000 description 2
- MHGGQXIPBPGZFB-UHFFFAOYSA-N methyl n-cyano-n'-methylcarbamimidothioate Chemical compound CSC(=NC)NC#N MHGGQXIPBPGZFB-UHFFFAOYSA-N 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- 239000011343 solid material Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- TUQOTMZNTHZOKS-UHFFFAOYSA-O tributylphosphanium Chemical compound CCCC[PH+](CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-O 0.000 description 2
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 2
- RXJKFRMDXUJTEX-UHFFFAOYSA-O triethylphosphanium Chemical compound CC[PH+](CC)CC RXJKFRMDXUJTEX-UHFFFAOYSA-O 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XPOZILPQFAIBOC-UHFFFAOYSA-N (5-methyl-1h-imidazol-4-yl)methanamine Chemical compound CC=1NC=NC=1CN XPOZILPQFAIBOC-UHFFFAOYSA-N 0.000 description 1
- GJFNRSDCSTVPCJ-UHFFFAOYSA-N 1,8-bis(dimethylamino)naphthalene Chemical compound C1=CC(N(C)C)=C2C(N(C)C)=CC=CC2=C1 GJFNRSDCSTVPCJ-UHFFFAOYSA-N 0.000 description 1
- NGKHWVKKYORAJL-UHFFFAOYSA-N 1-[(5-methyl-2-methylsulfanyl-1h-imidazol-4-yl)methyl]piperidine Chemical compound N1C(SC)=NC(CN2CCCCC2)=C1C NGKHWVKKYORAJL-UHFFFAOYSA-N 0.000 description 1
- ZORWZOOZJGMSTE-UHFFFAOYSA-N 1-cyano-2-methyl-3-(2-sulfanylethyl)guanidine Chemical compound N#CNC(=NC)NCCS ZORWZOOZJGMSTE-UHFFFAOYSA-N 0.000 description 1
- NHHVQVGXYLVKMF-UHFFFAOYSA-N 2-[(2,5-dimethyl-1h-imidazol-4-yl)methylsulfanyl]ethanamine Chemical compound CC1=NC(CSCCN)=C(C)N1 NHHVQVGXYLVKMF-UHFFFAOYSA-N 0.000 description 1
- YZZDTNIOUHTGEC-UHFFFAOYSA-N 2-[(2-benzyl-5-methyl-1h-imidazol-4-yl)methylsulfanyl]ethanamine Chemical compound NCCSCC1=C(C)NC(CC=2C=CC=CC=2)=N1 YZZDTNIOUHTGEC-UHFFFAOYSA-N 0.000 description 1
- RUVPQTGUBVQUNM-UHFFFAOYSA-N 2-[(2-butylsulfanyl-5-methyl-1h-imidazol-4-yl)methylsulfanyl]ethanamine Chemical compound CCCCSC1=NC(CSCCN)=C(C)N1 RUVPQTGUBVQUNM-UHFFFAOYSA-N 0.000 description 1
- QNNMSHUCESGONN-UHFFFAOYSA-N 2-[(2-ethylsulfanyl-5-methyl-1h-imidazol-4-yl)methylsulfanyl]ethanamine Chemical compound CCSC1=NC(CSCCN)=C(C)N1 QNNMSHUCESGONN-UHFFFAOYSA-N 0.000 description 1
- KYHBSTURXRCUEW-UHFFFAOYSA-N 2-[(2-methyl-1h-imidazol-5-yl)sulfanyl]ethanamine Chemical class CC1=NC=C(SCCN)N1 KYHBSTURXRCUEW-UHFFFAOYSA-N 0.000 description 1
- UEEMQUDIGWOBFB-UHFFFAOYSA-N 2-[(4-ethyl-1h-imidazol-5-yl)methylsulfanyl]ethanamine Chemical compound CCC=1NC=NC=1CSCCN UEEMQUDIGWOBFB-UHFFFAOYSA-N 0.000 description 1
- LOYWSNFTLDULFL-UHFFFAOYSA-N 2-[(5-methyl-2-phenylsulfanyl-1h-imidazol-4-yl)methylsulfanyl]ethanamine Chemical compound NCCSCC1=C(C)NC(SC=2C=CC=CC=2)=N1 LOYWSNFTLDULFL-UHFFFAOYSA-N 0.000 description 1
- MJZJRYUPMNKDQR-UHFFFAOYSA-N 2-aminoethanethiol;dihydrochloride Chemical compound Cl.Cl.NCCS MJZJRYUPMNKDQR-UHFFFAOYSA-N 0.000 description 1
- OGMADIBCHLQMIP-UHFFFAOYSA-N 2-aminoethanethiol;hydron;chloride Chemical compound Cl.NCCS OGMADIBCHLQMIP-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- KWPQTFXULUUCGD-UHFFFAOYSA-N 3,4,5,7,8,9,10,10a-octahydropyrido[1,2-a][1,4]diazepine Chemical compound C1CCN=CC2CCCCN21 KWPQTFXULUUCGD-UHFFFAOYSA-N 0.000 description 1
- GIJUPFHEPFPJCU-UHFFFAOYSA-N 4-(methoxymethyl)-2,5-dimethyl-1h-imidazole Chemical compound COCC=1N=C(C)NC=1C GIJUPFHEPFPJCU-UHFFFAOYSA-N 0.000 description 1
- VPEHTSWTVNLEIP-UHFFFAOYSA-N 4-(methoxymethyl)-5-methyl-1h-imidazole;hydrochloride Chemical compound Cl.COCC=1N=CNC=1C VPEHTSWTVNLEIP-UHFFFAOYSA-N 0.000 description 1
- RABMNRLVZSWVMX-UHFFFAOYSA-N 4-[(5-methyl-2-methylsulfanyl-1h-imidazol-4-yl)methyl]morpholine Chemical compound N1C(SC)=NC(CN2CCOCC2)=C1C RABMNRLVZSWVMX-UHFFFAOYSA-N 0.000 description 1
- DVPXBJGIIKBPJQ-UHFFFAOYSA-N 5-methyl-2-methylsulfanyl-4-(pyrrolidin-1-ylmethyl)-1h-imidazole Chemical compound N1C(SC)=NC(CN2CCCC2)=C1C DVPXBJGIIKBPJQ-UHFFFAOYSA-N 0.000 description 1
- 102000003710 Histamine H2 Receptors Human genes 0.000 description 1
- 108090000050 Histamine H2 Receptors Proteins 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000003810 Jones reagent Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FPBPLBWLMYGIQR-UHFFFAOYSA-N Metiamide Chemical compound CNC(=S)NCCSCC=1N=CNC=1C FPBPLBWLMYGIQR-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- GANYMSDHMBJFIL-UHFFFAOYSA-N acetonitrile;ethoxyethane Chemical compound CC#N.CCOCC GANYMSDHMBJFIL-UHFFFAOYSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- RIMGDBZXWSGBQN-UHFFFAOYSA-N burimamide Chemical compound CNC(=S)NCCCCC1=CN=C[N]1 RIMGDBZXWSGBQN-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 229940097265 cysteamine hydrochloride Drugs 0.000 description 1
- QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical compound NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 description 1
- KPVWDKBJLIDKEP-UHFFFAOYSA-L dihydroxy(dioxo)chromium;sulfuric acid Chemical compound OS(O)(=O)=O.O[Cr](O)(=O)=O KPVWDKBJLIDKEP-UHFFFAOYSA-L 0.000 description 1
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 1
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- YKWNUSJLICDQEO-UHFFFAOYSA-N ethoxyethane;propan-2-ol Chemical compound CC(C)O.CCOCC YKWNUSJLICDQEO-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- LDEUOXNBCIACJK-UHFFFAOYSA-N guanidine pentanimidamide 2-phenylethanimidamide propanimidamide 2,2,2-trifluoroethanimidamide Chemical compound C1(=CC=CC=C1)CC(=N)N.FC(C(=N)N)(F)F.C(CCCC)(=N)N.C(CC)(=N)N.NC(=N)N LDEUOXNBCIACJK-UHFFFAOYSA-N 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- LBVZYUZDHIPGLN-UHFFFAOYSA-N imidazol-1-ylmethanethiol Chemical compound SCN1C=CN=C1 LBVZYUZDHIPGLN-UHFFFAOYSA-N 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- NNBBQNFHCVVQHZ-UHFFFAOYSA-N methyl carbamimidothioate;sulfuric acid Chemical compound CSC(N)=N.OS(O)(=O)=O NNBBQNFHCVVQHZ-UHFFFAOYSA-N 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- QNJKCKMBDGMOHY-UHFFFAOYSA-N n,n-dimethyl-1-(5-methyl-1h-imidazol-4-yl)methanamine Chemical compound CN(C)CC=1N=CNC=1C QNJKCKMBDGMOHY-UHFFFAOYSA-N 0.000 description 1
- MUSWOKMGTDDRKH-UHFFFAOYSA-N n-[(5-methyl-1h-imidazol-4-yl)methyl]butan-1-amine Chemical compound CCCCNCC=1N=CNC=1C MUSWOKMGTDDRKH-UHFFFAOYSA-N 0.000 description 1
- SIRDPIAWQZUDON-UHFFFAOYSA-N n-butyl-n-[(5-methyl-1h-imidazol-4-yl)methyl]butan-1-amine Chemical compound CCCCN(CCCC)CC=1N=CNC=1C SIRDPIAWQZUDON-UHFFFAOYSA-N 0.000 description 1
- IVSSOOPRPJEGBZ-UHFFFAOYSA-N n-methyl-1-(5-methyl-1h-imidazol-4-yl)methanamine Chemical compound CNCC=1N=CNC=1C IVSSOOPRPJEGBZ-UHFFFAOYSA-N 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- PMOIAJVKYNVHQE-UHFFFAOYSA-N phosphanium;bromide Chemical compound [PH4+].[Br-] PMOIAJVKYNVHQE-UHFFFAOYSA-N 0.000 description 1
- REJGOFYVRVIODZ-UHFFFAOYSA-N phosphanium;chloride Chemical class P.Cl REJGOFYVRVIODZ-UHFFFAOYSA-N 0.000 description 1
- 150000003003 phosphines Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- RCOSUMRTSQULBK-UHFFFAOYSA-N sodium;propan-1-olate Chemical compound [Na+].CCC[O-] RCOSUMRTSQULBK-UHFFFAOYSA-N 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 150000003585 thioureas Chemical class 0.000 description 1
- RXJKFRMDXUJTEX-UHFFFAOYSA-N triethylphosphine Chemical compound CCP(CC)CC RXJKFRMDXUJTEX-UHFFFAOYSA-N 0.000 description 1
- SCXZATZIVUFOFT-UHFFFAOYSA-N undec-5-ene Chemical compound [CH2]CCCC=CCCCCC SCXZATZIVUFOFT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
ABSTRACT OF THE DISCLOSURE
A process for preparing 4-(oxy, thio or amino)methyl-imidazole compounds via displacement of the trisubstituted phosphonium group from 4-(trisubstituted phosphonium)-methylimidazole compounds is disclosed. The process provides an efficient and high yield method of producing these imidazoles which are useful as intermediates in the preparation of pharmacologically active compounds such as histamine H2-antagonists.
A process for preparing 4-(oxy, thio or amino)methyl-imidazole compounds via displacement of the trisubstituted phosphonium group from 4-(trisubstituted phosphonium)-methylimidazole compounds is disclosed. The process provides an efficient and high yield method of producing these imidazoles which are useful as intermediates in the preparation of pharmacologically active compounds such as histamine H2-antagonists.
Description
1 This invention relates to a process for preparing substituted imidazole compounds which are useful intermediates in the preparation of compounds having pharmacological activity. In particular, the invention relates to a process for preparing 4-(oxy, thio or amino)-methylimidazoles via displacement of the trisubstituted phosphonium group from a 4-(trisubstituted phosphonium)-methylimidazole compound which is represented as follows:
Rl ~H2P (R ) 3 Rl CH2R2 ~N R2H ~ ~\ 5 ~/ H ~ ~ H + P ~R ) 3 I II
in which Rl is hydrogen or lower alkyl, preferably methyl;
R2 is methoxy, ethoxy, n-propoxy, n-butoxy, i-butoxy, NCN
Rl ~H2P (R ) 3 Rl CH2R2 ~N R2H ~ ~\ 5 ~/ H ~ ~ H + P ~R ) 3 I II
in which Rl is hydrogen or lower alkyl, preferably methyl;
R2 is methoxy, ethoxy, n-propoxy, n-butoxy, i-butoxy, NCN
2 t-butoxy~ -ScH2cH2NH2' -SCH2CH2NHC~ or -NR R
where R and R are each hydrogen, lower alkyl or together with the nitrogen atom to which they are attached form a piperidine, pyrrolidine or morpholine ring; R3 is hydrogen, lower alkyl, trifluoromethyl, benzyl, amino or -SR4 where R4 is lower alkyl, preferably methyl, phenyl, benzyl or chlorobenzyl; R5 is lower alkyl or, preferably, phenyl and X
is halo, preferably chloro or bromo. Preferably, R2 is ~, .
1 ~NCN
-SCH2CH2NH2 or -SCH2CH2NHC
The 4-(trisubstituted phosphonium)methyl-imidazole compounds of Fsrmula I are also objects of this invention.
As used herein, the term "lower alkyl" refers to groups containing from one to four carbon atoms.
According to the above process, the displacement ~ 5 of a trisubstituted phosphonium group [-P(R )3] of a compound of formula I is effected by reaction of a compound of formula I with R2H under basic conditions, that is with R2H in the form of its anion R2 ~. The anion may be formed from in situ reaction of a compound of the formula R2H and a strong base. Among the bases which may be used in the process of this invention are those which are cap~ble of removing the proton from a compound of the formula R2H to form the anion R2 ~ where R2 is defined as above. Such bases are those having a pKa greater than 12, for example the alkali metal alkoxides such as sodium methoxide or ethoxide or the metal hydrides such as sodium hydride which are preferred. When R2H is itself sufficiently basic, for example when R2H is piperidine, no additional base need be used. In those cases where R2H is extremely volatile, such as when R2 is -NR6R7 and one or both of R6 and R7 are hydrogen, it is preferable that R2H be in the form of a metalate, for example sodium or lithium metalate, such as sodium amide. Preferably, a slight excess of R2H is present.
where R and R are each hydrogen, lower alkyl or together with the nitrogen atom to which they are attached form a piperidine, pyrrolidine or morpholine ring; R3 is hydrogen, lower alkyl, trifluoromethyl, benzyl, amino or -SR4 where R4 is lower alkyl, preferably methyl, phenyl, benzyl or chlorobenzyl; R5 is lower alkyl or, preferably, phenyl and X
is halo, preferably chloro or bromo. Preferably, R2 is ~, .
1 ~NCN
-SCH2CH2NH2 or -SCH2CH2NHC
The 4-(trisubstituted phosphonium)methyl-imidazole compounds of Fsrmula I are also objects of this invention.
As used herein, the term "lower alkyl" refers to groups containing from one to four carbon atoms.
According to the above process, the displacement ~ 5 of a trisubstituted phosphonium group [-P(R )3] of a compound of formula I is effected by reaction of a compound of formula I with R2H under basic conditions, that is with R2H in the form of its anion R2 ~. The anion may be formed from in situ reaction of a compound of the formula R2H and a strong base. Among the bases which may be used in the process of this invention are those which are cap~ble of removing the proton from a compound of the formula R2H to form the anion R2 ~ where R2 is defined as above. Such bases are those having a pKa greater than 12, for example the alkali metal alkoxides such as sodium methoxide or ethoxide or the metal hydrides such as sodium hydride which are preferred. When R2H is itself sufficiently basic, for example when R2H is piperidine, no additional base need be used. In those cases where R2H is extremely volatile, such as when R2 is -NR6R7 and one or both of R6 and R7 are hydrogen, it is preferable that R2H be in the form of a metalate, for example sodium or lithium metalate, such as sodium amide. Preferably, a slight excess of R2H is present.
3~
iO84052 The reaction is carried out in an organic solvent with solvents such as methanol, ethanol, propanol, butanol, acetone, acetonitrile, dimethylformamide and dimethylsulfoxide being preferred. Preferably, the reaction is carried out at a temperature ranging from about ambient temperature to the reflux temperature of the solvent used in the reaction, viz. from about 25C. to about 200C., about 65C. to about 100C. being advantageous, for from about 20 minutes to about 24 hours, advantageously from about 20 minutes to about 3 hours.
Preferably, the reaction mixture is worked up by dilution with water and removal of the trialkyl- or triphenylphosphine by-product by filtration. Extraction of the filtrate when necessary followed by evaporation gives the compounds of formula II. It is often desirable to convert the compounds of formula II to the corresponding salts, preferably hydrochloride salts. Such salts are prepared by treating a solution of the imidazole of formula II with an acid or acid solution, for example with an ethereal or ethanolic solution of hydrochloric acid, and crystallizing the salt produced from an appropriate solvent.
The 4-(trisubstituted phosphonium)-methylimidazoles of formula I are prepared from reaction of a trisubstituted ~-acylvinylphosphonium halide, preferably bromide or chloride, of the formula .
(R5)3P ~ Rl where Rl, R5 and X are defined as ~) , above with a compound of the formula ~0t34052 H2N ~ NH where R3 is defined as above other than hydrogen, according to the procedure described by Zbiral, S Synthesis 11:775 (1974) and Zbiral and Hugl, Phosphorus 2:29 (1972). When R3 is hydrogen, the corresponding 4-(trisubstituted phosphonium)methylimidazoles of formula I are also prepared by reaction of trichloroacetamidine or formamidine sulfinic acid with a triphenyl ~-acylvinylphosphonium halide. In the formamidine sulfinic acid process a base is used, preferably a non-nucleophilic base such as a tertiary amine.
To prepare the trisubstituted ~-acylvinylphos-phonium halides not known to the art, a halovinyl alkyl ketone such as chlorovinyl methyl ketone is treated with a trialkyl- or triphenylphosphine. When Rl is hydrogen, the trisubstituted ~-formylvinylphosphonium halides are prepared by oxidation of a ~-haloallyl alcohol such as ~-chloroallyl alcohol and treatment of the product thus formed with a trialkyl- or triphenylphosphine.
The process of this invention provides an inexpensive, efficient and high yield method for preparing certain imidazoles useful as intermediates in the preparation of pharmacologically active compounds. A
further advantage of this process for the conversion of 2.5 compounds of formula I to those of formula II is that the trisubstituted phosphines, P(R5)3, formed during the course of the reaction may be easily removed from the reaction mixture and recycled or otherwise reused.
The imidazole compounds of formula II prepared by the process of this invention are useful as intermediates for the production of pharmacologically active compounds 1 in particular histamine H2-antagonists, for example N-cyano-N'-methyl-N"-[2-(5-Rl-imidazolylmethylthio)ethyl]-guanidine and N-methyl-N'-[2-(5-Rl-imidazolylmethylthio)-ethyl]thiourea compounds. Histamine H2-antagonists act at histamine H2-receptors which as described by Black et al.
[Nature 236:385 (1972)] may be defined as those histamine receptors which are not blocked by "antihistamines" such as mepyramine but are blocked by burimamide. Blockade of histamine ~2-receptors is of utility in inhibiting the biological actions of histamine which are not inhibited by "antihistamines". Histamine H2-antagonists are useful, for example, as inhibitors of gastric acid secretion.
Conversion of the compounds of formula II to the pharmacologically active guanidine and thiourea products can be accomplished in a variety of ways. When R2 is -SCH2CH2NH2 and R3 is hydrogen, lower alkyl, trifluoro-methyl, benzyl or amino, the 4-(2-aminoethyl)thiomethyl-imidazole compound of formula II is treated with methyl isothiocyanate to give the corresponding N-methyl-N'-[2-(5-Rl-imidazolylmethylthio~ethyl]thioureas. Reaction of the same 4-(2-aminoethyl)thiomethylimidazole compound with N-cyano-N',S-dimethylisothiourea gives the corresponding N-cyano-N'-methyl-N"-[2-(5-Rl-imidazolyl-methylthio)ethyl]guanidines. The guanidine products ~ are also prepared by reaction of the 4-(2-aminoethyl)-_5 thiomethylimidazole with dimethyl-N-cyanoimidodithio-carbonate and subsequently reacting the resulting N-cyano-N'-[2-(5-Rl-imidazolylmethylthio)ethyl]-S-methylisothiourea with methylamine. When R2 is 3~
1 ~NCN
SCH2C~2NHC~ , the guanidine products are prepared directly by the process of this invention.
When R2 is -SCH2CH2NH2 and R3 is -SR4 where R4 is defined as above, the compounds of formula II are treated with a reducing agent, for example, with Raney nickel, to give the corresponding 4-(2-aminoethyl)thio-methylimidazoles where R3 is hydrogen which are then converted to the guanidine and thiourea products as NCN
described above. When R2 is -SCH2CH2NHC \ and R3 is -SR4, treatment with a reducing agent gives the guanidine product directly.
When R2 is methoxy, ethoxy, n-propoxy, n-butoxy, i-butoxy, t-butoxy or -NR R and R3 is -SR4 where R4 is defined as above, the -SR4 group of the compounds of formula II is removed as described above and the products thus formed are then treated with cysteamine to give the
iO84052 The reaction is carried out in an organic solvent with solvents such as methanol, ethanol, propanol, butanol, acetone, acetonitrile, dimethylformamide and dimethylsulfoxide being preferred. Preferably, the reaction is carried out at a temperature ranging from about ambient temperature to the reflux temperature of the solvent used in the reaction, viz. from about 25C. to about 200C., about 65C. to about 100C. being advantageous, for from about 20 minutes to about 24 hours, advantageously from about 20 minutes to about 3 hours.
Preferably, the reaction mixture is worked up by dilution with water and removal of the trialkyl- or triphenylphosphine by-product by filtration. Extraction of the filtrate when necessary followed by evaporation gives the compounds of formula II. It is often desirable to convert the compounds of formula II to the corresponding salts, preferably hydrochloride salts. Such salts are prepared by treating a solution of the imidazole of formula II with an acid or acid solution, for example with an ethereal or ethanolic solution of hydrochloric acid, and crystallizing the salt produced from an appropriate solvent.
The 4-(trisubstituted phosphonium)-methylimidazoles of formula I are prepared from reaction of a trisubstituted ~-acylvinylphosphonium halide, preferably bromide or chloride, of the formula .
(R5)3P ~ Rl where Rl, R5 and X are defined as ~) , above with a compound of the formula ~0t34052 H2N ~ NH where R3 is defined as above other than hydrogen, according to the procedure described by Zbiral, S Synthesis 11:775 (1974) and Zbiral and Hugl, Phosphorus 2:29 (1972). When R3 is hydrogen, the corresponding 4-(trisubstituted phosphonium)methylimidazoles of formula I are also prepared by reaction of trichloroacetamidine or formamidine sulfinic acid with a triphenyl ~-acylvinylphosphonium halide. In the formamidine sulfinic acid process a base is used, preferably a non-nucleophilic base such as a tertiary amine.
To prepare the trisubstituted ~-acylvinylphos-phonium halides not known to the art, a halovinyl alkyl ketone such as chlorovinyl methyl ketone is treated with a trialkyl- or triphenylphosphine. When Rl is hydrogen, the trisubstituted ~-formylvinylphosphonium halides are prepared by oxidation of a ~-haloallyl alcohol such as ~-chloroallyl alcohol and treatment of the product thus formed with a trialkyl- or triphenylphosphine.
The process of this invention provides an inexpensive, efficient and high yield method for preparing certain imidazoles useful as intermediates in the preparation of pharmacologically active compounds. A
further advantage of this process for the conversion of 2.5 compounds of formula I to those of formula II is that the trisubstituted phosphines, P(R5)3, formed during the course of the reaction may be easily removed from the reaction mixture and recycled or otherwise reused.
The imidazole compounds of formula II prepared by the process of this invention are useful as intermediates for the production of pharmacologically active compounds 1 in particular histamine H2-antagonists, for example N-cyano-N'-methyl-N"-[2-(5-Rl-imidazolylmethylthio)ethyl]-guanidine and N-methyl-N'-[2-(5-Rl-imidazolylmethylthio)-ethyl]thiourea compounds. Histamine H2-antagonists act at histamine H2-receptors which as described by Black et al.
[Nature 236:385 (1972)] may be defined as those histamine receptors which are not blocked by "antihistamines" such as mepyramine but are blocked by burimamide. Blockade of histamine ~2-receptors is of utility in inhibiting the biological actions of histamine which are not inhibited by "antihistamines". Histamine H2-antagonists are useful, for example, as inhibitors of gastric acid secretion.
Conversion of the compounds of formula II to the pharmacologically active guanidine and thiourea products can be accomplished in a variety of ways. When R2 is -SCH2CH2NH2 and R3 is hydrogen, lower alkyl, trifluoro-methyl, benzyl or amino, the 4-(2-aminoethyl)thiomethyl-imidazole compound of formula II is treated with methyl isothiocyanate to give the corresponding N-methyl-N'-[2-(5-Rl-imidazolylmethylthio~ethyl]thioureas. Reaction of the same 4-(2-aminoethyl)thiomethylimidazole compound with N-cyano-N',S-dimethylisothiourea gives the corresponding N-cyano-N'-methyl-N"-[2-(5-Rl-imidazolyl-methylthio)ethyl]guanidines. The guanidine products ~ are also prepared by reaction of the 4-(2-aminoethyl)-_5 thiomethylimidazole with dimethyl-N-cyanoimidodithio-carbonate and subsequently reacting the resulting N-cyano-N'-[2-(5-Rl-imidazolylmethylthio)ethyl]-S-methylisothiourea with methylamine. When R2 is 3~
1 ~NCN
SCH2C~2NHC~ , the guanidine products are prepared directly by the process of this invention.
When R2 is -SCH2CH2NH2 and R3 is -SR4 where R4 is defined as above, the compounds of formula II are treated with a reducing agent, for example, with Raney nickel, to give the corresponding 4-(2-aminoethyl)thio-methylimidazoles where R3 is hydrogen which are then converted to the guanidine and thiourea products as NCN
described above. When R2 is -SCH2CH2NHC \ and R3 is -SR4, treatment with a reducing agent gives the guanidine product directly.
When R2 is methoxy, ethoxy, n-propoxy, n-butoxy, i-butoxy, t-butoxy or -NR R and R3 is -SR4 where R4 is defined as above, the -SR4 group of the compounds of formula II is removed as described above and the products thus formed are then treated with cysteamine to give the
4-(2-aminoethyl)thiomethylimidazole compounds where R3 is hydrogen which are converted to the guanidine and thiourea products as previously described.
When R is methoxy, ethoxy, n-propoxy, n-butoxy, i-butoxy, t-butoxy or -NR6R7 and R3 is hydrogen, the compounds of formula II are treated with cysteamine to give the 4-(2-aminoethyl)thiomethylimidazoles which are then converted to the guanidine and thiourea products as previously described.
1 These thiourea and cyanoguanidine products prepared from the compounds of formula II are described in U.S. Patents 3,950,333 and 3,950,353.
The following examples illustrate the invention but are not intended to limit the scope thereof.
Temperatures are in degrees Centigrade (C.) unless otherwise indicated.
Sodium metal (25.3 g., 1.1 mole) was dissolved in ethanol (2 L). 2-Methylpseudothiourea sulfate (278.3 g., 1.0 mole) was added and the mixture was stirred for O.S
hour. Then 411 g. (1.0 mole) of triphenyl B-acetyl-vinylphosphonium bromide was added and the mixture was heated at reflux for 18 hours, cooled and filtered. The filter cake was washed with 200 ml. of ethanol. The filtrate and ethanol wash were combined and evaporated under reduced pressure to leave a brown residue. Chloroform (500 ml.) was added to the residue and the mixture was stirred for a few minutes, then filtered. The filter cake was washed three times with 150 ml. portions of chloroform and dried to give 364 g. (75%) of [(2-methylthio-5-methyl-imidazolyl)-4-methyl]triphenylphosphonium bromide.
Cysteamine (12.23 g., 0.13 mole) was dissolved in 100 ml. methanol and 46.5 ml. of 25% wt/v sodium methoxide solution added. After stirring at ambient temperature for 10 minutes, the solid phosphonium salt was added and the mixture was refluxed for 20 minutes. The solution was diluted with twice its volume of ice water and stirred.
The precipitated triphenyl phosphine was removed by filtration. The filtrate was extracted with three 100 ml.
1 portions of chloroform and the chloroform extracts were dried and evaporated to dryness to yield 19 g. (86%) of 4-(2-aminoethyl)thiomethyl-5-methyl-2-methylthioimidazole as a viscous oil.
Treatment of 4-(2-aminoethyl)thiomethyl-5-methyl-2-methylthioimidazole with ethanolic hydrochloric acid ga~e the corresponding dihydrochloride salt, m.p. 165 (ethanol-ethyl acetate).
A solution of 48.3 g. (0.1 mole) of [t5-methyl-2-methylthioimidazolyl)-4-methyl]triphenylphosphonium bromide in 250 ml. of methanol was added rapidly at ambient temperature to a stirred solution of 35 ml. of 25~ sodium methoxide i~ methanol in 250 ml. of methanol. The mixture was refluxed for 20 minutes then concentrated to half the volume. After dilution with 900 ml. of water, the tri-phenyl phosphine was removed ~y filtration. The aqueous solution was extracted twice with 150 ml. portions of benzene and then three times with 250 ml. portions of chloroform. The chloroform extracts were dried (MgSO4) and evaporated to dryness to give 13 g. (76%) of 4-methoxymethyl-5-methyl-2-methylthioimidazole.
Sodium metal (2.3 g., 0.1 mole) was dissolved in ethanol and 9.5 g. (0.1 mole) of acetamidine hydrochloride was added with stirring. After 10 minutes 41.1 g. (0.1 mole) of triphenyl ~-acetylvinylphosphonium bromide was added and the mixture was refluxed for 17 hours. The mixture was filtered and the filtrate evaporated to dryness to give a tan solid which was digested with 300 ml. of _g_ 1 chloroform. Ethyl acetate (100 ml.) was added and the precipitate was collected by filtration and washed with 100 ml. of acetone to give 36 g. (80~) of [(2,5-dimethyl-imidazolyl)-4-methyl]triphenylphosphonium bromide.
When an equivalent amount of [(2,5-dimethyl-imidazolyl)-4-methyl]triphenylphosphonium bromide is substituted into the procedures of Examples 1 and 2 for [(2-methylthio-5-methylimidazolyl)-4-methyl]triphenyl-phosphonium bromide, 4-(2-aminoethyl)thiomethyl-2,5-dimethylimidazole and 2,5-dimethyl-4-methoxymethylimidazole are prepared, respectively.
(a) Trichloroacetamidine (1.62 g., 0.1 mole) was dissolved in 20 ml. of dry dimethylsulfoxide and 4.1 g.
(0.1 mole) of triphenyl ~-acetylvinylphosphonium bromide in 40 ml. of dimethylsulfoxide was added in one portion with stirring. The exothermic reaction mixture gradually lightened in color and was heated at 100 for 10 minutes.
Evaporation of the solvent gave [(5-methylimidazolyl)-4-methyl]triphenylphosphonium bromide.
Alternatively, and preferably, the phosphonium bromide is prepared using trichloroacetamidine by the following procedures:
Triphenyl ~-acetylvinylphosphonium bromide (8.0 g., 0.019 mole) was dissolved in a minimum amount of dry acetonitrile (about 100 ml.) and trichloroacetamidine 14.0 g., 0.25 mole) was added in one portion. The resulting mixture was stirred at room temperature and the material which crystallized out was filtered off to give [(2-trichloromethyl-
When R is methoxy, ethoxy, n-propoxy, n-butoxy, i-butoxy, t-butoxy or -NR6R7 and R3 is hydrogen, the compounds of formula II are treated with cysteamine to give the 4-(2-aminoethyl)thiomethylimidazoles which are then converted to the guanidine and thiourea products as previously described.
1 These thiourea and cyanoguanidine products prepared from the compounds of formula II are described in U.S. Patents 3,950,333 and 3,950,353.
The following examples illustrate the invention but are not intended to limit the scope thereof.
Temperatures are in degrees Centigrade (C.) unless otherwise indicated.
Sodium metal (25.3 g., 1.1 mole) was dissolved in ethanol (2 L). 2-Methylpseudothiourea sulfate (278.3 g., 1.0 mole) was added and the mixture was stirred for O.S
hour. Then 411 g. (1.0 mole) of triphenyl B-acetyl-vinylphosphonium bromide was added and the mixture was heated at reflux for 18 hours, cooled and filtered. The filter cake was washed with 200 ml. of ethanol. The filtrate and ethanol wash were combined and evaporated under reduced pressure to leave a brown residue. Chloroform (500 ml.) was added to the residue and the mixture was stirred for a few minutes, then filtered. The filter cake was washed three times with 150 ml. portions of chloroform and dried to give 364 g. (75%) of [(2-methylthio-5-methyl-imidazolyl)-4-methyl]triphenylphosphonium bromide.
Cysteamine (12.23 g., 0.13 mole) was dissolved in 100 ml. methanol and 46.5 ml. of 25% wt/v sodium methoxide solution added. After stirring at ambient temperature for 10 minutes, the solid phosphonium salt was added and the mixture was refluxed for 20 minutes. The solution was diluted with twice its volume of ice water and stirred.
The precipitated triphenyl phosphine was removed by filtration. The filtrate was extracted with three 100 ml.
1 portions of chloroform and the chloroform extracts were dried and evaporated to dryness to yield 19 g. (86%) of 4-(2-aminoethyl)thiomethyl-5-methyl-2-methylthioimidazole as a viscous oil.
Treatment of 4-(2-aminoethyl)thiomethyl-5-methyl-2-methylthioimidazole with ethanolic hydrochloric acid ga~e the corresponding dihydrochloride salt, m.p. 165 (ethanol-ethyl acetate).
A solution of 48.3 g. (0.1 mole) of [t5-methyl-2-methylthioimidazolyl)-4-methyl]triphenylphosphonium bromide in 250 ml. of methanol was added rapidly at ambient temperature to a stirred solution of 35 ml. of 25~ sodium methoxide i~ methanol in 250 ml. of methanol. The mixture was refluxed for 20 minutes then concentrated to half the volume. After dilution with 900 ml. of water, the tri-phenyl phosphine was removed ~y filtration. The aqueous solution was extracted twice with 150 ml. portions of benzene and then three times with 250 ml. portions of chloroform. The chloroform extracts were dried (MgSO4) and evaporated to dryness to give 13 g. (76%) of 4-methoxymethyl-5-methyl-2-methylthioimidazole.
Sodium metal (2.3 g., 0.1 mole) was dissolved in ethanol and 9.5 g. (0.1 mole) of acetamidine hydrochloride was added with stirring. After 10 minutes 41.1 g. (0.1 mole) of triphenyl ~-acetylvinylphosphonium bromide was added and the mixture was refluxed for 17 hours. The mixture was filtered and the filtrate evaporated to dryness to give a tan solid which was digested with 300 ml. of _g_ 1 chloroform. Ethyl acetate (100 ml.) was added and the precipitate was collected by filtration and washed with 100 ml. of acetone to give 36 g. (80~) of [(2,5-dimethyl-imidazolyl)-4-methyl]triphenylphosphonium bromide.
When an equivalent amount of [(2,5-dimethyl-imidazolyl)-4-methyl]triphenylphosphonium bromide is substituted into the procedures of Examples 1 and 2 for [(2-methylthio-5-methylimidazolyl)-4-methyl]triphenyl-phosphonium bromide, 4-(2-aminoethyl)thiomethyl-2,5-dimethylimidazole and 2,5-dimethyl-4-methoxymethylimidazole are prepared, respectively.
(a) Trichloroacetamidine (1.62 g., 0.1 mole) was dissolved in 20 ml. of dry dimethylsulfoxide and 4.1 g.
(0.1 mole) of triphenyl ~-acetylvinylphosphonium bromide in 40 ml. of dimethylsulfoxide was added in one portion with stirring. The exothermic reaction mixture gradually lightened in color and was heated at 100 for 10 minutes.
Evaporation of the solvent gave [(5-methylimidazolyl)-4-methyl]triphenylphosphonium bromide.
Alternatively, and preferably, the phosphonium bromide is prepared using trichloroacetamidine by the following procedures:
Triphenyl ~-acetylvinylphosphonium bromide (8.0 g., 0.019 mole) was dissolved in a minimum amount of dry acetonitrile (about 100 ml.) and trichloroacetamidine 14.0 g., 0.25 mole) was added in one portion. The resulting mixture was stirred at room temperature and the material which crystallized out was filtered off to give [(2-trichloromethyl-
5-methylimidazolyl)-4-methyl]triphenylphosphonium bromide.
1 This phosphonium salt (15.0 g., 0.027 mole) was added to 150 ml. of methanol and the resulting mixture was refluxed for three hours. The mixture was concentrated to about 15 ml. and the solid material was filtered off to give [(2-methoxycarbonyl-5-methylimidazolyl)-4-methyl]triphenyl-phosphonium bromide.
The above prepared phosphonium salt is heated to its melt1ng point (approximately 170) and held at this temperature until the evolution of gas is complete. On cooling, the solid product is triturated with chloroform to give ~(5-methylimidazolyl)-4-methyl]triphenylphosphonium bromide.
Triphenyl ~-acetylvinylphosphonium chloride t36 g., 0.01 mole) and trichloroacetamidine (16.1 g., 0.1 mole) were stirred in 200 ml. of methanol for one hour. The solution was heated to reflux, cooled and the methanol evaporated to leave [(2-methoxycarbonyl-5~methylimidazolyl)-4-methyl]-triphenylphosphonium chloride. Heating this phosphonium chloride salt at 170 until evolution of gas is complete, then cooling and triturating with chloroform gives [(5-methylimidazolyl)-4-me_hyl]triphenylphosphonium chloride.
(b) Formamidine sulfinic acid (11.0 g., 0.1 mole) was suspended in 250 ml. of dry dimethylsulfoxide and 2.4 g. (0.1 mole) of sodium hydride was added. After cessation of hydrogen gas evolution 36.5 g. (0.1 mole) of triphenyl 3-acetylvinylphosphonium chloride was added and the mixture was stirred for one hour at ambient temperature, then heated at 100 for 10 minutes. After cooling, the dimethylsulfoxide was evaporated and the 3~ residue was dissolved in 300 ml. of 1:1 chloroform-methanol 1 and the solution filtered. The filtrate was evaporated to dryness and the residue was recrystallized from chloroform-acetone to give 20 g. (50%) of [(5-methylimidazolyl)-4-methyl]triphenylphosphonium chloride, m.p. 223-225.
Alternatively, and preferably, [(5-methylimidazolyl)-4-methyl]triphenylphosphonium chloride and bromide are prepared using formamidine sulfinic acid by the following procedures:
Triphenyl ~-acetylvinylphosphonium chloride (3.65 g., 0.01 mole) and formamidine sulfinic acid (1.1 g., 0.01 mole) were dissolved in 50 ml. of dimethylsulfoxide. 1,8-bis-(nimethylamino)naphthalene ("proton sponge") (Z.14 g., 0.01 mole) was added and the mixture warmed to 80. After cooling, evaporating the dimethylsulfoxide, precipitating the inorganic salts with chloroform, filtering, evaporating to dryness and recrystallizing the residue from chloroform-acetone, an essentially quantitative yield of [(5-methylimidazolyl)-4-methyl]triphenylphosphonium chloride was obtained.
Triphenyl ~-acetylvinylphosphonium bromide (20.6 g., 0.05 mole) and formamidine sulfinic acid (6.0 g., slight excess over 0.05 mole) were dissolved in 100 ml. of dimethylsulfoxide.
1,5-DiazabicyclolS.4.0]undec-5-ene (DBU)(7.6 g., 0.05 mole) was added dropwise with stirring. The mixture was maintained 2 at 80 for 20 minutes and the dimethylsulfoxide was evaporated off. The residue was taken up in chloroform and inorganic salts were removed by filtration. The filtrate was evaporated to dryness and the residue was recrystallized from chloroform-acetone to give 1(5-methylimidazolyl)-4-methyl3triphenyl-phosphonium bromide in 80% yield.
~08405Z
1 To a sclution of 39~3 g. (0.1 mole) of [(5-methylimidazolyl)-4-methyl]triphenylphosphonium chloride in 200 ml. of methanol was added 22 ml. of 25% sodium methoxide in methanol and the re~ction mixture was refluxed for 1 hour. After cooling, the solution was diluted with three times its volume of water and filtered to remove triphenyl phosphine. The filtrate was extracted with four 125 ml.
portions of chloroform and the extracts were dried (MgSO4) and evaporated to dryness to yield 10.1 g. (80~) of 4-methoxymethyl-5-methylimidazole which was converted to the corresponding hydrochloride salt as described in Example 1, m.p. 150.
EXAMPLE S
- Triphenyl ~-acetylvinylphosphonium bromide (4.11 g., 0.01 mole) was added in one portion to a stirred suspension of 1.1 g. (0.01 mole) of formamidine sulfinic acid in 20 ml. of dimethylsulfoxide containing 0.25 g. of sodium hydride. The mixture was stirred at ambient temperature for 1 hour then at 80 for an additional hour. A solution of 0.99 g. (0.01 mole) of the sodium salt of cysteamine, prepared by addition of two equivalents of sodium methoxide to cysteamine dihydrochloride, in 10 ml.
of methanol was added and the resulting mixture was heated at 70-80 for 4 hours. The mixture was diluted with twice its volume of water and the triphenyl phosphine was removed by filtration. The filtrate was extracted with 100 ml. of toluene and with two 100 ml. ~ortions of chloroform. The chloroform extracts were combined, dried (MgSO4) and evaporated to dryness to give 4-(2-aminoethyl)thiomethyl-5-methylimidazole.
~08~1~5Z
1 Alternatively, and preferably, the above described reaction of triphenyl ~-acetylvinylphosphonium bromide and formamidine sulfinic acid is carried out using 1,8-bis-(dimethylamino)naphthalene or 1,5-diazabicyclo[5.4.0]undec-5-ene by the procedures described in Example 4~b).
When an equivalent amount of triphenyl ~-ethylcarbonylvinylphosphonium bromide or triphenyl ~-isopropylcarbonylvinylphosphonium bromide is allowed to react with formamidine sulfinic acid as described in the procedure of Example 4, [(5-ethylimidazolyl)-4-methyl]-triphenylphosphonium bromide and [(5-isopropylimidazolyl)-4-methyl]triphenylphosphonium bromide are prepared, respectively.
Reaction of [(5-ethylimidazolyl)-4-methyl]-triphenylphosphonium bromide and [(5-isopropylimidazolyl)-4-methyl]triphenylphosphonium bromide with cysteamine in the presence of sodium methoxide or sodium hydride as described above gives 4-(2-aminoethyl)thiomethyl-5-ethylimidazole and 4-~2-aminoethyl)thiomethyl-5-isopropylimidazole, respectively.
In a similar manner, the triphenylphosphonium group of [(5-ethylimidazolyl)-4-methyl]triphenylphosphonium bromide and r(5-isopropylimidazolyl)-4-methyl]triphenyl-phosphonium bromide is displaced by reaction with other nucleophiles by procedures described herein.
When [(5-methylimidazolyl-4-methyl]triphenyl-phosphonium bromide is allowed to react with sodium ethoxide in ethanol, sodium n-propoxide in n-propanol or sodium t-butoxide in t-butanol according to thQ procedure described in Example 4(b), the following imidazole compounds are ~084052 obtained:
4-ethoxymethyl-5-methylimidazole 5-methyl-4-n-propoxymethylimidazole 4-t-butoxymethyl-5-methylimidazole.
Substitution of a salt of a 2-substituted pseudothiourea listed below:
2-ethylpseudothiourea 2-butylpseudothiourea 2-benzylpseudothiourea 2-phenylpseudothiourea 2-(4-chlorobenzyl)pseudothiourea in the procedure of Example l in place of 2-methylpseudo-thiourea sulfate gives the following triphenylphosphonium bromide compounds:
[(2-ethylthio-5-methylimidazolyl)-4-methyl]-triphenylphosphonium bromide l(2-butylthio-5-methylimidazolyl)-4-methyl]-triphenylphosphonium bromide [(2-benzylthio-5-methylimidazolyl)-4-methyl]-triphenylphosphonium bromide [(5-methyl-2-phenylthioimidazolyl)-4-methyl]-triphenylphosphonium bromide [(2-(4-chlorobenzyl)thio-5-methylimidazolyl)-4-methyl]triphenylphosphonium bromide.
Reaction of a triphenylphosphonium bromide listed above with cysteamine as described in Example 1 gives the imidazole compounds listed below:
4-(2-aminoethyl)thiomethyl-2-ethylthio-5-methylimidazole 1084~52 1 4-(2-aminoethyl)thiomethyl-2-butylthio-5-methylimidazole 4-(2-aminoethyl)thiomethyl-2-benæylthio-5-methylimidazole 4-(2-aminoethyl)thiomethyl-5-methyl-2-phenylthioimidazole 4-(2-aminoethyl)thiomethyl-2-(4-chlorobenzyl)-thio-5-methylimidazole.
Substitution of a salt of a substituted amidine listed below:
guanidine propionamidine valeramidine 2,2,2-trifluoroacetamidine 2-phenylacetamidine in the procedure of Example 3 for acetamidine hydrochloride gives the triphenylphosphonium bromides listed below:
[(2-amino-5-methylimidazolyl)-4-methyl]triphenyl-phosphonium bromide [(2-ethyl-5-methylimidazolyl)-4-methyl]triphenyl-phosphonium bromide [(2-butyl-5-methylimidazolyl)-4-methyl]triphenyl-phosphonium bromide [(5-methyl-2-trifluoromethylimidazolyl)-4-methyl]-triphenylphosphonium bromide ~(2-benzyl-5-methylimidazolyl)-4-methyl]triphenyl-phosphonium bromide.
Reaction of a triphenylphosphonium bromide listed above with cysteamine as described in the procedure of Example 1 gives the following imidazole compounds:
1 2-amino-4-(2-aminoethyl)thiomethyl-5-methyl-imidazole 4-(2-aminoethyl)thiomethyl-2-ethyl-5-methyl-imidazole 4-(2-aminoethyl)thiomethyl-2-butyl-5-methyl-imidazole 4-(2-aminoethyl)thiomethyl-5-methyl-2-trifluoro-methylimidazole 4-(2-aminoethyl)thiomethyl-2-benzyl-5-methyl-imidazole.
To a solution of 9.25 g. (0.1 mole) of B-chloroallyl alcohol in 100 ml. of benzene is added an equivalent amount of an aqueous solution of chromic acid-sulfuric acid (Jones reagent) and the mixture is stirred at ambient temperature for 1 hour. After filtering, the layers are separated and the organic phase is washed with water. Triphenyl phosphine (26.2 g., 0.1 mole) is added to the benzene solution and it is heated to reflux. The precipitate which forms upon cooling is collected by filtration and dried to give B-formylvinylphosphonium chloride.
When an equivalent amount of B-formylvinyl-phosphonium chloride is allowed to react with formamidine sulfinic acid as described in the procedure of Example 4, (imidazolyl-4-methyl)triphenylphosphonium chloride is prepared.
Reaction of (imidazolyl-4-methyl)triphenyl-phosphonium chloride with cysteamine in the presence of sodium methoxide or sodium hydride as described hereinabove gives 4-(2-aminoethyl)thiomethylimidazole.
~(~84~52 1 I~ a similar manner, the triphenylphosphonium group of (imidazolyl-4-methyl)triphenylphosphonium chloride is displaced by reaction with other nucleophiles by procedures described herein.
EXAMPLE ll Tri-n-butylphosphine (20.2 g., 0.1 mole) is added to a solution of 10.4 g. (0.1 mole) of chlorovinyl methyl ketone in 250 ml. of benzene and the mixture is refluxed for l hour. The mixture is cooled and the precipitated material is collected by filtration and dried to give tri-n-butyl ~-acetylvinylphosphonium chloride.
Triethyl ~-acetylvinylphosphonium chloride is prepared as described above by use of triethylphosphine in place of tri-n-butylphosphine.
Reaction of an equivalent amount of tri-n-butyl ~-acetylvinylphosphonium chloride or triethyl ~-acetylvinylphosphonium chloride with formamidine sulfinic acid as described in the procedure of Example 4 gives [(5-methylimidazolyl)-4-methyl]tri-n-butylphosphonium chloride and [(5-methylimidazolyl)-4-methyl]triethylphos-phonium chloride, respectively.
Reaction of [(5-methylimidazolyl)-4-methyl]tri-n-butylphosphonium chloride or [(5-methylimidazolyl)-4-methyl~triethylphosphonium chloride with cysteamine in the presence of sodium methoxide or sodium hydride as described hereinabove gives 4-(2-aminoethyl)thiomethyl-5-methyl-imidazole.
Sodium amide (0.39 g., 0.01 mole) was dissolved in 40 ml. of liquid ammonia and 4.11 g. (0.01 mole) of 3~
1 [(5-methylimidazolyl)-4-methyl]triphenylphosphonium bromide was added. The suspension was stirred at -40C. for one hour and then allowed to warm to room temperature as the ammonia evaporated. The triphenyl phosphine was extracted from the residue with benzene and the remaining solids were taken up in water and extracted with chloroform. The chloroform extracts were dried and evaporated to give 4-aminomethyl-5-methylimidazole in 70% yield. This amine was refluxed with a molar equivalent of cysteamine in acetic acid and treated with hydrochloric acid to give 4-(2-amino-ethyl)thiomethyl-5-methylimidazole dihydrochloride.
[(5-Methyl-2-methylthioimidazolyl)-4-methyl]-triphenylphosphonium bromide (4.83 g., 0.01 mole) was stirred in 20 ml. of piperidine at room temperature for 30 minutes, then refluxed for one hour, cooled and filtered. The filtrate was evaporated under reduced pressure and chromatographed on a silica gel column using chloroform/methanol as eluant to yield 5-methyl-2-methylthio-4-piperidinomethylimidazole.
Treating with hydrochloric acid and refluxing the resulting dihydrochloride salt with one molar equivalent of cysteamine in acetic acid gave 4-(2-aminoethyl)thiomethyl-5-methyl-2-methylthioimidazole dihydrochloride.
By the same procedure, using pyrrolidine in place of piperidine, 5-methyl-2-methylthio-4-pyrrolidinomethyl-imidazole is prepared.
Similarly, using morpholine in place of piperidine, 5-methyl-2-methylthio-4-morpholinomethylimidazole is prepared.
Converting these pyrrolidine and morpholine compounds to the dihydrochloride salts and treating with 1 cysteamine in acetic acid gives 4-(2-aminoethyl)thiomethyl-5-methyl-2-methylthioimidazole dihydrochloride.
Dimethylamine (0.5 g., 0.01 mole) was dissolved in 35 ml. of tetrahydrofuran, stirred and cooled in an ice bath while 5 ml. (0.01 mole) of 2M butyl lithium in hexane was added dropwise with stirring. After stirring the mixture for 15 minutes in the cold, 3.93 g. (0.01 mole) of [(5-methyl-imidazolyl)-4-methyl]triphenylphosphonium chloride was added and the solution allowed to warm to room temperature. After stirring for two hours at room temperature, the solvents were evaporated and the residue treated with 50 ml. of water.
Filtration yielded diphenyl phosphine. The aqueous filtrate was extracted with chloroform, dried and evaporated to afford 4-(N,N-dimethylaminomethyl)-5-methylimidazole. This amine was then refluxed with a molar equivalent of cysteamine in acetic acid and treated with hydrochloric acid to give 4-(2-aminoethyl)thiomethyl-S-methylimidazole dihydrochloride.
By the same procedure, using methylamine in place of dimethylamine, 4-(N-methylaminomethyl)-5-methylimidazole is prepared. In the same way, using butylamine and dibutylamine, 4-(N-butylaminomethyl)-5-methylimidazole and 4-(N,N-dibutylaminomethyl)-5-methylimidazole are prepared.
Refluxing these intermediates with cysteamine by the above 2 procedure and treating with hydrochloric acid gives 4-(2-aminoethyl)thiomethyl-5-methylimidazole dihydrochloxide.
N-Cyano-N'-methyl-N"-mercaptoethylguanidine (1.58 g., 0.01 mole) was dissolved in 15 ml. of methanol and 2.3 ml. of sodium methoxide in methanol was added. After ~o8405Z
1 stirring at room temperature for five minutes, a suspension of 3.93 g. of [(5-methylimidazolyl)-4-methyl]triphenyl-phosphonium chloride in 10 ml. of methanol was added. The solution was heated to reflux. An equal volume of water was added and most of the methanol was removed by evaporation.
Filtration and water washing afforded triphenylphosphine. The filtrate was treated with charcoal, filtered and concentrated.
Filtration gave N-cyano-N'-methyl-N"-[2-(5-methyl-4-imidazolylmethylthio)ethyl]guanidine.
A mixture of 6.6 g. (0.03 mole) of 4-(2-amino-ethyl)thiomethyl-5-methyl-2-methylthioimidazole and 6.6.g.
of 50:50 nickel-aluminum alloy in 50 ml. of formic acid was refluxed for 3 hours. The metals were removed by L5 filtration and the filtrate was evaporated to dryness. The residue was dissolved in ethanol and the ethanolic solution was saturated with hydrogen sulfide then filtered. The filtrate was saturated with hydrogen chloride. Addition of ethyl acetate caused precipitation of 4-(2-aminoethyl)-thiomethyl-5-methylimidazole as the dihydrochloride salt.
In a similar manner, the 2-substituted thio group is removed from the other imidazole compounds in which R3 is a substituted thio group prepared hereinabove.
Potassium carbonate (7.75 g.) was added to a solution of 14.6 g. of 4-(2-aminoethyl)thiomethyl-5-methylimidaæole dihydrochloride in 120 ml. of water. The solution was maintained at ambient temperature for 15 mi~utes and 5.15 g. of methyl isothiocyanate was added.
After heating under reflux for 0.5 hour, the solution was slowly cooled to 5. The product was collected and 1 recrystallized from water to give N-methyl-N'-[2-(5-methyl-4-imidazolylmethylthio)ethyl]thiourea, m.p. 150-152.
4-Methoxymethyl-5-methyl-2-methylthioimidazole (13.46 g., 0.078 mole) and ca. 25 g. of Raney nickel were added to 400 ml. of ethanol and the mixture was refluxed for 3 hours. The mixture was filtered and the filter cake was washed with 25 ml. of ethanol. The filtrate and washings were combined and hydrogen sulfide gas was passed into the solution for 10 minutes. The mixture was filtered and the filtrate was evaporated to dryness to give 8.63 g.
(88%) of 4-methoxymethyl-5-methylimidazole.
4-Methoxymethyl-5-methylimidazole was converted to the corresponding hydrochloride salt as described above.
4-Methoxymethyl-5-methylimidazole hydrochloride (4.9 g., 0.03 mole) an~ 3.4 g. (0.03 mole) of cysteamine hydrochloride were dissolved in a minimum amount of acetic acid and the mixture was refluxed for 18 hours. After cooling in an ice bath, the mixture was filtered to give 5.8 g. (80~) of 4-(2-aminoethyl)thiomethyl-5-methyl-imidazole dihydrochloride salt.
Similarly, the other imidazoles prepared hereinabove in which R2 is an alkoxy group and R3 is a substituted thio group are reacted with Raney nickel followed by treatment of the product thus formed with cysteamine in acetic acid to give the corresponding 4-(2-aminoethyl)thiomethyl imidazoles.
(a) A solution of 17.0 g. of 4-(2-a~inoethyl)-thiomethyl-5-methylimidazole and 11.2 g. of N-cyano-N',S-dimethylisothiourea in 500 ml. of acetonitrile was refluxed 1084~Z
for 24 hours. The mixture was concentrated and the residue was chromatographed on a column of silica gel with acetonitrile as eluant. The product obtained was recrystallized from acetonitrile-ether to give N-cyano-N'-methyl-N"- [2-(5-methyl-4-imidazolylmethylthio)ethyl]-guanidine, m.p. 141-142.
(b) A solution of 23.4 g. of 4- (2-aminoethyl)-thiomethyl-5-methylimidazole in ethanol was added slowly to a solution of 20.0 g. of dimethyl-N-cyanoimidodithiocar-bonate in ethanol, with stirring at ambient temperature.
Filtration afforded N-cyano-N'-[2-(5-methyl-4-imidazolyl-methylthio)ethyl]-S-methylisothiourea, m.p. 148-150.
The filtrate was concentrated under reduced pressure and the mixture was triturated with cold water to give a solid material which was collected by filtration and recrystallized twice from isopropanol-ether, m.p. 148-150.
A solution of 75 ml. of 33% methylamine in ethanol was added to a solution of 10.1 g. of N-cyano-N'-[2- (5-methyl-4-imidazolylmethylthio)ethyl]-S-methylisothiourea in 30 ml. of ethanol. The reaction mixture was set aside at ambient temperature for 2.5 hours. Following concentration under reduced pressure, the residue was recrystallized twice from isopropanol-petroleum ether to give N-cyano-N'-methyl-N"-[2-(5-methyl-4-imidazolylmethylthio)ethyl]guanidine, m.p.
141-143.
Using [(2-methylthio-5-methylimidazolyl)-4-methyl]triphenylphosphonium bromide in place of the phosphonium compound in the procedure of Example 15 1 gives N-cyano-N'-methyl-N"-[2-(2-methylthio-5-methyl-4-imidazolylmethylthio)ethyl3guanidine. The 2-methylthio group is removed by refluxing a mixture of the compound and 50:50 nickel-aluminum alloy in formic acid and working up by the procedure of Example 16 to give N-cyano-N'-methyl-N"-[2-(5-methyl-4-imidazolylmethylthio)ethyl]-guanidine.
1 This phosphonium salt (15.0 g., 0.027 mole) was added to 150 ml. of methanol and the resulting mixture was refluxed for three hours. The mixture was concentrated to about 15 ml. and the solid material was filtered off to give [(2-methoxycarbonyl-5-methylimidazolyl)-4-methyl]triphenyl-phosphonium bromide.
The above prepared phosphonium salt is heated to its melt1ng point (approximately 170) and held at this temperature until the evolution of gas is complete. On cooling, the solid product is triturated with chloroform to give ~(5-methylimidazolyl)-4-methyl]triphenylphosphonium bromide.
Triphenyl ~-acetylvinylphosphonium chloride t36 g., 0.01 mole) and trichloroacetamidine (16.1 g., 0.1 mole) were stirred in 200 ml. of methanol for one hour. The solution was heated to reflux, cooled and the methanol evaporated to leave [(2-methoxycarbonyl-5~methylimidazolyl)-4-methyl]-triphenylphosphonium chloride. Heating this phosphonium chloride salt at 170 until evolution of gas is complete, then cooling and triturating with chloroform gives [(5-methylimidazolyl)-4-me_hyl]triphenylphosphonium chloride.
(b) Formamidine sulfinic acid (11.0 g., 0.1 mole) was suspended in 250 ml. of dry dimethylsulfoxide and 2.4 g. (0.1 mole) of sodium hydride was added. After cessation of hydrogen gas evolution 36.5 g. (0.1 mole) of triphenyl 3-acetylvinylphosphonium chloride was added and the mixture was stirred for one hour at ambient temperature, then heated at 100 for 10 minutes. After cooling, the dimethylsulfoxide was evaporated and the 3~ residue was dissolved in 300 ml. of 1:1 chloroform-methanol 1 and the solution filtered. The filtrate was evaporated to dryness and the residue was recrystallized from chloroform-acetone to give 20 g. (50%) of [(5-methylimidazolyl)-4-methyl]triphenylphosphonium chloride, m.p. 223-225.
Alternatively, and preferably, [(5-methylimidazolyl)-4-methyl]triphenylphosphonium chloride and bromide are prepared using formamidine sulfinic acid by the following procedures:
Triphenyl ~-acetylvinylphosphonium chloride (3.65 g., 0.01 mole) and formamidine sulfinic acid (1.1 g., 0.01 mole) were dissolved in 50 ml. of dimethylsulfoxide. 1,8-bis-(nimethylamino)naphthalene ("proton sponge") (Z.14 g., 0.01 mole) was added and the mixture warmed to 80. After cooling, evaporating the dimethylsulfoxide, precipitating the inorganic salts with chloroform, filtering, evaporating to dryness and recrystallizing the residue from chloroform-acetone, an essentially quantitative yield of [(5-methylimidazolyl)-4-methyl]triphenylphosphonium chloride was obtained.
Triphenyl ~-acetylvinylphosphonium bromide (20.6 g., 0.05 mole) and formamidine sulfinic acid (6.0 g., slight excess over 0.05 mole) were dissolved in 100 ml. of dimethylsulfoxide.
1,5-DiazabicyclolS.4.0]undec-5-ene (DBU)(7.6 g., 0.05 mole) was added dropwise with stirring. The mixture was maintained 2 at 80 for 20 minutes and the dimethylsulfoxide was evaporated off. The residue was taken up in chloroform and inorganic salts were removed by filtration. The filtrate was evaporated to dryness and the residue was recrystallized from chloroform-acetone to give 1(5-methylimidazolyl)-4-methyl3triphenyl-phosphonium bromide in 80% yield.
~08405Z
1 To a sclution of 39~3 g. (0.1 mole) of [(5-methylimidazolyl)-4-methyl]triphenylphosphonium chloride in 200 ml. of methanol was added 22 ml. of 25% sodium methoxide in methanol and the re~ction mixture was refluxed for 1 hour. After cooling, the solution was diluted with three times its volume of water and filtered to remove triphenyl phosphine. The filtrate was extracted with four 125 ml.
portions of chloroform and the extracts were dried (MgSO4) and evaporated to dryness to yield 10.1 g. (80~) of 4-methoxymethyl-5-methylimidazole which was converted to the corresponding hydrochloride salt as described in Example 1, m.p. 150.
EXAMPLE S
- Triphenyl ~-acetylvinylphosphonium bromide (4.11 g., 0.01 mole) was added in one portion to a stirred suspension of 1.1 g. (0.01 mole) of formamidine sulfinic acid in 20 ml. of dimethylsulfoxide containing 0.25 g. of sodium hydride. The mixture was stirred at ambient temperature for 1 hour then at 80 for an additional hour. A solution of 0.99 g. (0.01 mole) of the sodium salt of cysteamine, prepared by addition of two equivalents of sodium methoxide to cysteamine dihydrochloride, in 10 ml.
of methanol was added and the resulting mixture was heated at 70-80 for 4 hours. The mixture was diluted with twice its volume of water and the triphenyl phosphine was removed by filtration. The filtrate was extracted with 100 ml. of toluene and with two 100 ml. ~ortions of chloroform. The chloroform extracts were combined, dried (MgSO4) and evaporated to dryness to give 4-(2-aminoethyl)thiomethyl-5-methylimidazole.
~08~1~5Z
1 Alternatively, and preferably, the above described reaction of triphenyl ~-acetylvinylphosphonium bromide and formamidine sulfinic acid is carried out using 1,8-bis-(dimethylamino)naphthalene or 1,5-diazabicyclo[5.4.0]undec-5-ene by the procedures described in Example 4~b).
When an equivalent amount of triphenyl ~-ethylcarbonylvinylphosphonium bromide or triphenyl ~-isopropylcarbonylvinylphosphonium bromide is allowed to react with formamidine sulfinic acid as described in the procedure of Example 4, [(5-ethylimidazolyl)-4-methyl]-triphenylphosphonium bromide and [(5-isopropylimidazolyl)-4-methyl]triphenylphosphonium bromide are prepared, respectively.
Reaction of [(5-ethylimidazolyl)-4-methyl]-triphenylphosphonium bromide and [(5-isopropylimidazolyl)-4-methyl]triphenylphosphonium bromide with cysteamine in the presence of sodium methoxide or sodium hydride as described above gives 4-(2-aminoethyl)thiomethyl-5-ethylimidazole and 4-~2-aminoethyl)thiomethyl-5-isopropylimidazole, respectively.
In a similar manner, the triphenylphosphonium group of [(5-ethylimidazolyl)-4-methyl]triphenylphosphonium bromide and r(5-isopropylimidazolyl)-4-methyl]triphenyl-phosphonium bromide is displaced by reaction with other nucleophiles by procedures described herein.
When [(5-methylimidazolyl-4-methyl]triphenyl-phosphonium bromide is allowed to react with sodium ethoxide in ethanol, sodium n-propoxide in n-propanol or sodium t-butoxide in t-butanol according to thQ procedure described in Example 4(b), the following imidazole compounds are ~084052 obtained:
4-ethoxymethyl-5-methylimidazole 5-methyl-4-n-propoxymethylimidazole 4-t-butoxymethyl-5-methylimidazole.
Substitution of a salt of a 2-substituted pseudothiourea listed below:
2-ethylpseudothiourea 2-butylpseudothiourea 2-benzylpseudothiourea 2-phenylpseudothiourea 2-(4-chlorobenzyl)pseudothiourea in the procedure of Example l in place of 2-methylpseudo-thiourea sulfate gives the following triphenylphosphonium bromide compounds:
[(2-ethylthio-5-methylimidazolyl)-4-methyl]-triphenylphosphonium bromide l(2-butylthio-5-methylimidazolyl)-4-methyl]-triphenylphosphonium bromide [(2-benzylthio-5-methylimidazolyl)-4-methyl]-triphenylphosphonium bromide [(5-methyl-2-phenylthioimidazolyl)-4-methyl]-triphenylphosphonium bromide [(2-(4-chlorobenzyl)thio-5-methylimidazolyl)-4-methyl]triphenylphosphonium bromide.
Reaction of a triphenylphosphonium bromide listed above with cysteamine as described in Example 1 gives the imidazole compounds listed below:
4-(2-aminoethyl)thiomethyl-2-ethylthio-5-methylimidazole 1084~52 1 4-(2-aminoethyl)thiomethyl-2-butylthio-5-methylimidazole 4-(2-aminoethyl)thiomethyl-2-benæylthio-5-methylimidazole 4-(2-aminoethyl)thiomethyl-5-methyl-2-phenylthioimidazole 4-(2-aminoethyl)thiomethyl-2-(4-chlorobenzyl)-thio-5-methylimidazole.
Substitution of a salt of a substituted amidine listed below:
guanidine propionamidine valeramidine 2,2,2-trifluoroacetamidine 2-phenylacetamidine in the procedure of Example 3 for acetamidine hydrochloride gives the triphenylphosphonium bromides listed below:
[(2-amino-5-methylimidazolyl)-4-methyl]triphenyl-phosphonium bromide [(2-ethyl-5-methylimidazolyl)-4-methyl]triphenyl-phosphonium bromide [(2-butyl-5-methylimidazolyl)-4-methyl]triphenyl-phosphonium bromide [(5-methyl-2-trifluoromethylimidazolyl)-4-methyl]-triphenylphosphonium bromide ~(2-benzyl-5-methylimidazolyl)-4-methyl]triphenyl-phosphonium bromide.
Reaction of a triphenylphosphonium bromide listed above with cysteamine as described in the procedure of Example 1 gives the following imidazole compounds:
1 2-amino-4-(2-aminoethyl)thiomethyl-5-methyl-imidazole 4-(2-aminoethyl)thiomethyl-2-ethyl-5-methyl-imidazole 4-(2-aminoethyl)thiomethyl-2-butyl-5-methyl-imidazole 4-(2-aminoethyl)thiomethyl-5-methyl-2-trifluoro-methylimidazole 4-(2-aminoethyl)thiomethyl-2-benzyl-5-methyl-imidazole.
To a solution of 9.25 g. (0.1 mole) of B-chloroallyl alcohol in 100 ml. of benzene is added an equivalent amount of an aqueous solution of chromic acid-sulfuric acid (Jones reagent) and the mixture is stirred at ambient temperature for 1 hour. After filtering, the layers are separated and the organic phase is washed with water. Triphenyl phosphine (26.2 g., 0.1 mole) is added to the benzene solution and it is heated to reflux. The precipitate which forms upon cooling is collected by filtration and dried to give B-formylvinylphosphonium chloride.
When an equivalent amount of B-formylvinyl-phosphonium chloride is allowed to react with formamidine sulfinic acid as described in the procedure of Example 4, (imidazolyl-4-methyl)triphenylphosphonium chloride is prepared.
Reaction of (imidazolyl-4-methyl)triphenyl-phosphonium chloride with cysteamine in the presence of sodium methoxide or sodium hydride as described hereinabove gives 4-(2-aminoethyl)thiomethylimidazole.
~(~84~52 1 I~ a similar manner, the triphenylphosphonium group of (imidazolyl-4-methyl)triphenylphosphonium chloride is displaced by reaction with other nucleophiles by procedures described herein.
EXAMPLE ll Tri-n-butylphosphine (20.2 g., 0.1 mole) is added to a solution of 10.4 g. (0.1 mole) of chlorovinyl methyl ketone in 250 ml. of benzene and the mixture is refluxed for l hour. The mixture is cooled and the precipitated material is collected by filtration and dried to give tri-n-butyl ~-acetylvinylphosphonium chloride.
Triethyl ~-acetylvinylphosphonium chloride is prepared as described above by use of triethylphosphine in place of tri-n-butylphosphine.
Reaction of an equivalent amount of tri-n-butyl ~-acetylvinylphosphonium chloride or triethyl ~-acetylvinylphosphonium chloride with formamidine sulfinic acid as described in the procedure of Example 4 gives [(5-methylimidazolyl)-4-methyl]tri-n-butylphosphonium chloride and [(5-methylimidazolyl)-4-methyl]triethylphos-phonium chloride, respectively.
Reaction of [(5-methylimidazolyl)-4-methyl]tri-n-butylphosphonium chloride or [(5-methylimidazolyl)-4-methyl~triethylphosphonium chloride with cysteamine in the presence of sodium methoxide or sodium hydride as described hereinabove gives 4-(2-aminoethyl)thiomethyl-5-methyl-imidazole.
Sodium amide (0.39 g., 0.01 mole) was dissolved in 40 ml. of liquid ammonia and 4.11 g. (0.01 mole) of 3~
1 [(5-methylimidazolyl)-4-methyl]triphenylphosphonium bromide was added. The suspension was stirred at -40C. for one hour and then allowed to warm to room temperature as the ammonia evaporated. The triphenyl phosphine was extracted from the residue with benzene and the remaining solids were taken up in water and extracted with chloroform. The chloroform extracts were dried and evaporated to give 4-aminomethyl-5-methylimidazole in 70% yield. This amine was refluxed with a molar equivalent of cysteamine in acetic acid and treated with hydrochloric acid to give 4-(2-amino-ethyl)thiomethyl-5-methylimidazole dihydrochloride.
[(5-Methyl-2-methylthioimidazolyl)-4-methyl]-triphenylphosphonium bromide (4.83 g., 0.01 mole) was stirred in 20 ml. of piperidine at room temperature for 30 minutes, then refluxed for one hour, cooled and filtered. The filtrate was evaporated under reduced pressure and chromatographed on a silica gel column using chloroform/methanol as eluant to yield 5-methyl-2-methylthio-4-piperidinomethylimidazole.
Treating with hydrochloric acid and refluxing the resulting dihydrochloride salt with one molar equivalent of cysteamine in acetic acid gave 4-(2-aminoethyl)thiomethyl-5-methyl-2-methylthioimidazole dihydrochloride.
By the same procedure, using pyrrolidine in place of piperidine, 5-methyl-2-methylthio-4-pyrrolidinomethyl-imidazole is prepared.
Similarly, using morpholine in place of piperidine, 5-methyl-2-methylthio-4-morpholinomethylimidazole is prepared.
Converting these pyrrolidine and morpholine compounds to the dihydrochloride salts and treating with 1 cysteamine in acetic acid gives 4-(2-aminoethyl)thiomethyl-5-methyl-2-methylthioimidazole dihydrochloride.
Dimethylamine (0.5 g., 0.01 mole) was dissolved in 35 ml. of tetrahydrofuran, stirred and cooled in an ice bath while 5 ml. (0.01 mole) of 2M butyl lithium in hexane was added dropwise with stirring. After stirring the mixture for 15 minutes in the cold, 3.93 g. (0.01 mole) of [(5-methyl-imidazolyl)-4-methyl]triphenylphosphonium chloride was added and the solution allowed to warm to room temperature. After stirring for two hours at room temperature, the solvents were evaporated and the residue treated with 50 ml. of water.
Filtration yielded diphenyl phosphine. The aqueous filtrate was extracted with chloroform, dried and evaporated to afford 4-(N,N-dimethylaminomethyl)-5-methylimidazole. This amine was then refluxed with a molar equivalent of cysteamine in acetic acid and treated with hydrochloric acid to give 4-(2-aminoethyl)thiomethyl-S-methylimidazole dihydrochloride.
By the same procedure, using methylamine in place of dimethylamine, 4-(N-methylaminomethyl)-5-methylimidazole is prepared. In the same way, using butylamine and dibutylamine, 4-(N-butylaminomethyl)-5-methylimidazole and 4-(N,N-dibutylaminomethyl)-5-methylimidazole are prepared.
Refluxing these intermediates with cysteamine by the above 2 procedure and treating with hydrochloric acid gives 4-(2-aminoethyl)thiomethyl-5-methylimidazole dihydrochloxide.
N-Cyano-N'-methyl-N"-mercaptoethylguanidine (1.58 g., 0.01 mole) was dissolved in 15 ml. of methanol and 2.3 ml. of sodium methoxide in methanol was added. After ~o8405Z
1 stirring at room temperature for five minutes, a suspension of 3.93 g. of [(5-methylimidazolyl)-4-methyl]triphenyl-phosphonium chloride in 10 ml. of methanol was added. The solution was heated to reflux. An equal volume of water was added and most of the methanol was removed by evaporation.
Filtration and water washing afforded triphenylphosphine. The filtrate was treated with charcoal, filtered and concentrated.
Filtration gave N-cyano-N'-methyl-N"-[2-(5-methyl-4-imidazolylmethylthio)ethyl]guanidine.
A mixture of 6.6 g. (0.03 mole) of 4-(2-amino-ethyl)thiomethyl-5-methyl-2-methylthioimidazole and 6.6.g.
of 50:50 nickel-aluminum alloy in 50 ml. of formic acid was refluxed for 3 hours. The metals were removed by L5 filtration and the filtrate was evaporated to dryness. The residue was dissolved in ethanol and the ethanolic solution was saturated with hydrogen sulfide then filtered. The filtrate was saturated with hydrogen chloride. Addition of ethyl acetate caused precipitation of 4-(2-aminoethyl)-thiomethyl-5-methylimidazole as the dihydrochloride salt.
In a similar manner, the 2-substituted thio group is removed from the other imidazole compounds in which R3 is a substituted thio group prepared hereinabove.
Potassium carbonate (7.75 g.) was added to a solution of 14.6 g. of 4-(2-aminoethyl)thiomethyl-5-methylimidaæole dihydrochloride in 120 ml. of water. The solution was maintained at ambient temperature for 15 mi~utes and 5.15 g. of methyl isothiocyanate was added.
After heating under reflux for 0.5 hour, the solution was slowly cooled to 5. The product was collected and 1 recrystallized from water to give N-methyl-N'-[2-(5-methyl-4-imidazolylmethylthio)ethyl]thiourea, m.p. 150-152.
4-Methoxymethyl-5-methyl-2-methylthioimidazole (13.46 g., 0.078 mole) and ca. 25 g. of Raney nickel were added to 400 ml. of ethanol and the mixture was refluxed for 3 hours. The mixture was filtered and the filter cake was washed with 25 ml. of ethanol. The filtrate and washings were combined and hydrogen sulfide gas was passed into the solution for 10 minutes. The mixture was filtered and the filtrate was evaporated to dryness to give 8.63 g.
(88%) of 4-methoxymethyl-5-methylimidazole.
4-Methoxymethyl-5-methylimidazole was converted to the corresponding hydrochloride salt as described above.
4-Methoxymethyl-5-methylimidazole hydrochloride (4.9 g., 0.03 mole) an~ 3.4 g. (0.03 mole) of cysteamine hydrochloride were dissolved in a minimum amount of acetic acid and the mixture was refluxed for 18 hours. After cooling in an ice bath, the mixture was filtered to give 5.8 g. (80~) of 4-(2-aminoethyl)thiomethyl-5-methyl-imidazole dihydrochloride salt.
Similarly, the other imidazoles prepared hereinabove in which R2 is an alkoxy group and R3 is a substituted thio group are reacted with Raney nickel followed by treatment of the product thus formed with cysteamine in acetic acid to give the corresponding 4-(2-aminoethyl)thiomethyl imidazoles.
(a) A solution of 17.0 g. of 4-(2-a~inoethyl)-thiomethyl-5-methylimidazole and 11.2 g. of N-cyano-N',S-dimethylisothiourea in 500 ml. of acetonitrile was refluxed 1084~Z
for 24 hours. The mixture was concentrated and the residue was chromatographed on a column of silica gel with acetonitrile as eluant. The product obtained was recrystallized from acetonitrile-ether to give N-cyano-N'-methyl-N"- [2-(5-methyl-4-imidazolylmethylthio)ethyl]-guanidine, m.p. 141-142.
(b) A solution of 23.4 g. of 4- (2-aminoethyl)-thiomethyl-5-methylimidazole in ethanol was added slowly to a solution of 20.0 g. of dimethyl-N-cyanoimidodithiocar-bonate in ethanol, with stirring at ambient temperature.
Filtration afforded N-cyano-N'-[2-(5-methyl-4-imidazolyl-methylthio)ethyl]-S-methylisothiourea, m.p. 148-150.
The filtrate was concentrated under reduced pressure and the mixture was triturated with cold water to give a solid material which was collected by filtration and recrystallized twice from isopropanol-ether, m.p. 148-150.
A solution of 75 ml. of 33% methylamine in ethanol was added to a solution of 10.1 g. of N-cyano-N'-[2- (5-methyl-4-imidazolylmethylthio)ethyl]-S-methylisothiourea in 30 ml. of ethanol. The reaction mixture was set aside at ambient temperature for 2.5 hours. Following concentration under reduced pressure, the residue was recrystallized twice from isopropanol-petroleum ether to give N-cyano-N'-methyl-N"-[2-(5-methyl-4-imidazolylmethylthio)ethyl]guanidine, m.p.
141-143.
Using [(2-methylthio-5-methylimidazolyl)-4-methyl]triphenylphosphonium bromide in place of the phosphonium compound in the procedure of Example 15 1 gives N-cyano-N'-methyl-N"-[2-(2-methylthio-5-methyl-4-imidazolylmethylthio)ethyl3guanidine. The 2-methylthio group is removed by refluxing a mixture of the compound and 50:50 nickel-aluminum alloy in formic acid and working up by the procedure of Example 16 to give N-cyano-N'-methyl-N"-[2-(5-methyl-4-imidazolylmethylthio)ethyl]-guanidine.
Claims (15)
1. A process for preparing a compound of the formula:
in which:
R1 is hydrogen or lower alkyl;
R2 is methoxy, ethoxy, n-propoxy, n-butoxy, i-butoxy, t-butoxy, -SCH2CH2NH2, or -NR6R7 where R6 and R7 are each hydrogen, lower alkyl or together with the nitrogen atom to which they are attached form a piperidine, pyrrolidine or morpholine ring; and R3 is hydrogen, lower alkyl, trifluoromethyl, benzyl, amino or -SR4 where R4 is lower alkyl, phenyl, benzyl or chlorobenzyl, comprising reacting a compound of the formula:
in which:
R1 and R3 are defined as above;
R5 is lower alkyl or phenyl; and X is halo, with a compound of the formula R2-H where R2 is defined as above in an organic solvent under basic conditions.
in which:
R1 is hydrogen or lower alkyl;
R2 is methoxy, ethoxy, n-propoxy, n-butoxy, i-butoxy, t-butoxy, -SCH2CH2NH2, or -NR6R7 where R6 and R7 are each hydrogen, lower alkyl or together with the nitrogen atom to which they are attached form a piperidine, pyrrolidine or morpholine ring; and R3 is hydrogen, lower alkyl, trifluoromethyl, benzyl, amino or -SR4 where R4 is lower alkyl, phenyl, benzyl or chlorobenzyl, comprising reacting a compound of the formula:
in which:
R1 and R3 are defined as above;
R5 is lower alkyl or phenyl; and X is halo, with a compound of the formula R2-H where R2 is defined as above in an organic solvent under basic conditions.
2. A process according to claim 1 in which R2 is methoxy, ethoxy, n-propoxy, n-butoxy, i-butoxy, t-butoxy or -SCH2CH2NH2.
3. A process according to claim 1 in which R5 is phenyl.
4. A process according to claim 1 in which R2 is -SCH2CH2NH2 or .
5. A process according to claim 4 in which R5 is phenyl.
6. A process according to claim 1 in which R2 is or NR6R7.
7. A process according to claim 3 in which R2 is -SCH2CH2NH2 and R3 is -SR4 where R4 is methyl.
8. A process according to claim 3 in which R2 is -SCH2CH2NH2 and R3 is hydrogen.
9. A process according to claim 3 in which R2 is and R3 is hydrogen.
10. A process according to claim 7 for preparing 4-(2-aminoethyl)thiomethyl-5-methyl-2-methylthioimidazole.
11. A process according to claim 8 for preparing 4-(2-aminoethyl)thiomethyl-5-methylimidazole.
12. A process according to claim 1 in which sodium methoxide or sodium hydride are used to provide the basic conditions.
13. A process according to claim 1 in which the solvent is methanol, ethanol, propanol, butanol, acetone, acetonitrile, dimethylformamide or dimethylsulfoxide.
14. A process according to claim 1 in which the reaction is carried out at a temperature of from about 25°C. to about 200°C. for from about 20 minutes to about 24 hours.
15. A process according to claim 14 in which the reaction is carried out at a temperature of about 65°C. to about 100°C. for from about 20 minutes to about 3 hours.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US771,044 | 1977-02-22 | ||
US05/771,044 US4119781A (en) | 1975-10-29 | 1977-02-22 | Process for preparing 4-substituted imidazole compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1084052A true CA1084052A (en) | 1980-08-19 |
Family
ID=25090518
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA276,559A Expired CA1084052A (en) | 1977-02-22 | 1977-04-20 | Process for preparing 4-substituted imidazole compounds |
Country Status (22)
Country | Link |
---|---|
AR (1) | AR217073A1 (en) |
AT (1) | AT355015B (en) |
BE (1) | BE853954R (en) |
CA (1) | CA1084052A (en) |
CH (2) | CH631167A5 (en) |
DE (1) | DE2718715A1 (en) |
DK (1) | DK168277A (en) |
ES (1) | ES458153A1 (en) |
FI (1) | FI73208C (en) |
FR (1) | FR2381031A2 (en) |
GB (1) | GB1582865A (en) |
HU (1) | HU174840B (en) |
IE (1) | IE45035B1 (en) |
IL (1) | IL51898A (en) |
IN (1) | IN148285B (en) |
IT (1) | IT1078449B (en) |
LU (1) | LU77200A1 (en) |
MX (1) | MX4663E (en) |
NL (1) | NL7704617A (en) |
NO (1) | NO152903C (en) |
PT (1) | PT66446B (en) |
SE (2) | SE442199B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL57415A (en) * | 1978-05-30 | 1984-08-31 | Smith Kline French Lab | Nitropyrrole compounds,process for preparing them and pharmaceutical compositions containing them |
-
1977
- 1977-04-15 DK DK168277A patent/DK168277A/en not_active IP Right Cessation
- 1977-04-18 IL IL51898A patent/IL51898A/en unknown
- 1977-04-18 PT PT66446A patent/PT66446B/en unknown
- 1977-04-19 AR AR267273A patent/AR217073A1/en active
- 1977-04-20 CA CA276,559A patent/CA1084052A/en not_active Expired
- 1977-04-22 IT IT22790/77A patent/IT1078449B/en active
- 1977-04-22 FI FI771291A patent/FI73208C/en not_active IP Right Cessation
- 1977-04-22 HU HU77SI1570A patent/HU174840B/en unknown
- 1977-04-25 AT AT289577A patent/AT355015B/en not_active IP Right Cessation
- 1977-04-25 ES ES458153A patent/ES458153A1/en not_active Expired
- 1977-04-26 NO NO771453A patent/NO152903C/en unknown
- 1977-04-26 LU LU77200A patent/LU77200A1/xx unknown
- 1977-04-26 BE BE177015A patent/BE853954R/en not_active IP Right Cessation
- 1977-04-26 IE IE839/77A patent/IE45035B1/en unknown
- 1977-04-26 MX MX775683U patent/MX4663E/en unknown
- 1977-04-27 CH CH522577A patent/CH631167A5/en not_active IP Right Cessation
- 1977-04-27 GB GB17561/77A patent/GB1582865A/en not_active Expired
- 1977-04-27 FR FR7712797A patent/FR2381031A2/en active Granted
- 1977-04-27 DE DE19772718715 patent/DE2718715A1/en not_active Withdrawn
- 1977-04-27 SE SE7704870A patent/SE442199B/en not_active IP Right Cessation
- 1977-04-27 NL NL7704617A patent/NL7704617A/en not_active Application Discontinuation
-
1978
- 1978-04-25 IN IN305/DEL/78A patent/IN148285B/en unknown
-
1980
- 1980-12-18 SE SE8008935A patent/SE452887B/en not_active IP Right Cessation
-
1981
- 1981-10-09 CH CH648881A patent/CH631168A5/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
IL51898A (en) | 1980-07-31 |
GB1582865A (en) | 1981-01-14 |
NL7704617A (en) | 1978-08-24 |
FR2381031B2 (en) | 1982-09-17 |
FI73208B (en) | 1987-05-29 |
FI73208C (en) | 1987-09-10 |
NO152903C (en) | 1985-12-11 |
AR217073A1 (en) | 1980-02-29 |
NO771453L (en) | 1978-08-23 |
LU77200A1 (en) | 1977-08-17 |
ES458153A1 (en) | 1978-04-01 |
NO152903B (en) | 1985-09-02 |
IT1078449B (en) | 1985-05-08 |
IE45035B1 (en) | 1982-06-02 |
FR2381031A2 (en) | 1978-09-15 |
SE7704870L (en) | 1978-08-23 |
IN148285B (en) | 1981-01-03 |
DK168277A (en) | 1978-08-23 |
CH631167A5 (en) | 1982-07-30 |
SE442199B (en) | 1985-12-09 |
IE45035L (en) | 1978-08-22 |
CH631168A5 (en) | 1982-07-30 |
MX4663E (en) | 1982-07-21 |
AT355015B (en) | 1980-02-11 |
DE2718715A1 (en) | 1978-08-31 |
IL51898A0 (en) | 1977-06-30 |
FI771291A (en) | 1978-08-23 |
ATA289577A (en) | 1979-07-15 |
PT66446A (en) | 1977-05-01 |
HU174840B (en) | 1980-03-28 |
SE8008935L (en) | 1980-12-18 |
SE452887B (en) | 1987-12-21 |
BE853954R (en) | 1977-10-26 |
PT66446B (en) | 1978-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016006099A (en) | Ergothioneine and the like synthesis method | |
US4119781A (en) | Process for preparing 4-substituted imidazole compounds | |
CN101412733B (en) | Preparation of N-alkyl thiophosphoryl triamide by one-pot method | |
US4215217A (en) | Process for preparing 4-substituted imidazole compounds | |
US6018049A (en) | Process for the preparation of carbamoylated imidazole derivatives | |
CS208770B2 (en) | Method of making the quanidine derivatives | |
CA1084052A (en) | Process for preparing 4-substituted imidazole compounds | |
US4267337A (en) | Imidazolemethylphosphonium salts | |
FI79301B (en) | FOERFARANDE FOER FRAMSTAELLNING AV 4-METHYL-5- ALKYLTIOMETYLIMIDAZOLER. | |
US4049669A (en) | Process for preparing 5-(alkoxy- and aminoethyl thio)methylthiazole compounds | |
CS203054B2 (en) | Method of preparing imidazolyl compounds | |
IL33925A (en) | Phenyl-acetyl-guanidine derivatives,their preparation and pharmaceutical compositions containing them | |
CA1064940A (en) | Reduction process for the preparation of 4-(hydroxymethyl) imidazole compounds | |
US4063023A (en) | Process for preparing 4-(hydroxymethyl)imidazole compounds | |
CA1121363A (en) | Process to prepare n-cyano-n'-methyl-n''-(2-¬(4- methyl-5-imidazolyl)-methylthio|-ethyl) guanidine | |
CS261232B2 (en) | Method of 1(2-/5-dimethylamino methyl-2(furylmethylthio)ethyl/)amino-1-methylamino-2-nitroethylene production | |
JPS5910345B2 (en) | Production method of thiourea compound | |
HU195782B (en) | Process for production of n-cyan-n'-methil-n''-/2///-5-methil-1h-imidasole-4-il/-methil/-tio/-ethil/-guanidine | |
CA1154023A (en) | Process for preparing imidazole derivative | |
US2479525A (en) | Oxazolidines and a method of preparing the same | |
JP3727088B2 (en) | Process for producing substituted isothioureas | |
HU181097B (en) | Method and sheeting device for constructing linear reinforced concrete construction of closed section particularly public tunnel | |
JPH0344071B2 (en) | ||
JPH0637478B2 (en) | Process for producing substituted imidazole compound | |
NO150118B (en) | ANALOGUE PROCEDURE FOR PREPARING A THERAPEUTIC ACTIVE IMIDAZOLIDINE DERIVATE. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |